PROARC MEDICAL LTD

Their core work

PROARC Medical is an Israeli medical device SME developing the ClearRing system — a minimally invasive device for treating Benign Prostatic Hyperplasia (BPH), the chronic enlargement of the prostate that affects roughly half of men over 50. Their work focuses on translating a single, specific clinical concept from feasibility through full product development and commercialization. They used the EU SME Instrument (now EIC Accelerator) as their primary funding path, progressing from a Phase 1 feasibility grant to a Phase 2 development grant for the same product. Their profile is that of a focused, single-product medtech startup rather than a broad research organization.

What they specialise in

How they've shifted over time

PROARC's H2020 participation covers only 2018–2022 and represents a single product journey rather than a research evolution. There is no detectable shift in focus: both projects address the same clinical problem (BPH) with the same device concept (ClearRing). The progression is from proof-of-concept (Phase 1, EUR 50K, 2018) to funded development (Phase 2, EUR 1.94M, 2019–2022), which reflects product maturation, not a change in research direction. No keyword data was available to detect any deeper thematic shift.

PROARC appears to be a single-product company scaling toward market launch — a potential partner for clinical validation networks, urology distributors, or hospital procurement networks rather than research consortia.

How they like to work

PROARC has acted exclusively as coordinator across both its H2020 projects, but this is characteristic of SME Instrument grants, which are awarded to individual companies rather than consortia. No consortium partners are recorded, meaning they have operated entirely as a standalone grantee rather than as a collaborative research partner. Anyone considering working with PROARC should expect an entrepreneurial, product-focused counterpart rather than an academic collaborator experienced in multi-partner project management.

PROARC has no recorded consortium partners or cross-country collaborations within H2020. Their EU engagement is bilateral — directly with the European Commission via the SME Instrument — rather than through a collaborative research network.

What sets them apart

PROARC is one of a small number of Israeli medical device SMEs to successfully progress through both phases of the EU SME Instrument with the same product, which signals credibility with EU evaluators and a coherent commercialization story. Their focus on BPH — a high-prevalence condition with an aging European patient base — gives them a clear market entry angle. For a consortium builder in digital health, urology, or surgical devices, PROARC brings an actual clinical device at an advanced development stage rather than a research concept.

Highlights from their portfolio

• ClearRing (SME-2)
  The largest grant (EUR 1.94M, 2019–2022) represents a full EIC/SME Instrument Phase 2 award — a competitive grant that fewer than 5% of applicants receive — validating the clinical and commercial case for the ClearRing device.
• ClearRing (SME-1)
  The Phase 1 feasibility study (EUR 50K, 2018) is notable as the successful gateway that led directly to Phase 2 funding, confirming the organization's ability to execute against EU evaluation criteria.